Maze Therapeutics

MAZENasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$1.244 B

$22.39 -0.58%

Close of 21 Sept 2026

Revenue

$167.5M

#2348 by revenue

Earnings

-$131.1M

Loss-making

Shares outstanding

55,549,168

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#44Vor BiopharmaVOR$1.30B
#45MeiraGTxMGTX$1.26B
#46Maze TherapeuticsMAZE$1.24B
#47Replimune GroupREPL$1.21B
#48Odyssey TherapeuticsODTX$1.11B

What if Maze Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$544,995.64

Per share 24,341× higher

Bitcoin $1.72T

$30,960.03

Per share 1,383× higher

Nvidia $5.48T

$98,648.79

Per share 4,406× higher

Or at a round number

$2.00B $5.00B $10.0B $20.0B

Where these numbers come from

Share counts and financials for Maze Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.